Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT04730544	TitleEfficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )	Fase Fase 2	Date Added 2021-01-29	Ubicación Francia	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Ipilimumab, Nivolumab	Etiquetas MSI-H/ MMRd
NCT ID NCT04724239	TitleA Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma	Fase Fase 2	Date Added 2021-01-26	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas chidamide, IBI305, Sintilimab	Etiquetas MSS/ MMRp
NCT ID NCT04708470	TitlePhase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer	Fase Phase 1, Phase 2	Date Added 2021-01-14	Ubicación Maryland, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Bintrafusp alfa, Entinostat, NHS-IL12	Etiquetas MSS/ MMRp
NCT ID NCT04687631	TitleConversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases	Fase Fase 3	Date Added 2020-12-29	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas mFOLFOXIRI Plus Bevacizumab, mFOLFOXIRI plus Cetuximab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04660812	TitleAn Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.	Fase Phase 1, Phase 2	Date Added 2020-12-09	Ubicación Alabama, United States Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States Francia Italia Corea, República de España Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab	Etiquetas MSS/ MMRp
NCT ID NCT04659382	TitleStudy to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2020-12-09	Ubicación Francia	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Atezolizumab, Bevacizumab, TheraSphere, XELOX	Etiquetas MSS/ MMRp
NCT ID NCT04653480	TitleSurufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC	Fase Fase 2	Date Added 2020-12-04	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Chemotherapy, Surufatinib, Toripalimab	Etiquetas MSS/ MMRp
NCT ID NCT04626635	TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors	Fase Phase 1, Phase 2	Date Added 2020-11-12	Ubicación California, United States Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States Francia Israel Países Bajos Polonia España Turkey	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas cemiplimab, REGN7075	Etiquetas MSS/ MMRp
NCT ID NCT04607421	TitleA Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)	Fase Fase 3	Date Added 2020-10-29	Ubicación Arizona, United States California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Bélgica Brasil Bulgaria Canadá China Czechia Dinamarca Finland Alemania India Italia Japón Corea, República de Mexico Países Bajos Nueva Zelanda Noruega Polonia Russian Federation Slovakia Sudáfrica España Suecia Taiwán Ukraine Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas 5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin	Etiquetas MSS/ MMRp
NCT ID NCT04599140	TitleSX-682 y nivolumab para el tratamiento del cáncer colorrectal metastásico o irresecable con mutación del RAS, el ensayo STOPTRAFFIC-1	Fase Fase 1	Date Added 2020-10-22	Ubicación Texas, United States	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas CXCR1/2 Inhibitor SX-682, Nivolumab	Etiquetas MSS/ MMRp

Showing 141 to 150 of 299 entries